5E Advanced Materials 주식 (NASDAQ: FEAM)

에 대한 최신 뉴스 5E Advanced Materials (NASDAQ:FEAM) 주식

5E Advanced Materials

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

Mining.Big,Industrial,Infrastructure,Among,Mountains,In,Alberta,,Canada

Commodities

FEAM

GROY

MTAL

2024년 5월 28일 주요 뉴스 골드 로열티(NYSE:GROY): 밴쿠버에 본사를 둔 이 회사는 오리온 마인 파이낸스(Orion Mine Finance)로부터 바레스 실버 프로젝트(Vares Silver Project)의 구리 스트림을 5천만 달러에 구매하기로 합의했다. 지급액에는 현금 4,500만 달러와 500만 달러 상당의 골드 로열티 주식이 포함된다.

화요일 주요 광업 뉴스: 골드 로열티, BHP와 리오 틴토, 메탈스 에퀴지션 등

5E Advanced Materials, Inc. - Common Stock

5E Advanced Materials Inc

<p>Guggenheim  analyst John Heinbockel   reiterates Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) with a Buy and maintains $13 price target.</p>


News

Price Target

Reiteration

Analyst Ratings

XPOF

Guggenheim Reiterates Buy on Xponential Fitness, Maintains $13 Price Target

WIIM

SHOP

Shopify shares are trading higher after it was announced the stock will join the Nasdaq-100 beginning May 19.

Hamilton Beach Brands Holdings shares are trading higher after the company raised its quarterly cash dividend.

<p>Barclays  analyst Brandt Montour   maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Overweight and lowers the price target from $50 to $48.</p>


DKNG

Barclays Maintains Overweight on DraftKings, Lowers Price Target to $48

<p><a href="https://www.youtube.com/watch?v=u9kS0t0jkJs" title="https://www.youtube.com/watch?v=u9kS0t0jkJs">https://www.youtube.com/watch?v=u9kS0t0jkJs</a></p>


Macro Economic Events

Politics

Global

Economics

General

President Trump Says China Has Agreed To Stop Fentanyl; Big Incentive For China To Stop; Take China At Their Word

<p>Baird  analyst David Koning   downgrades TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) from Outperform to Neutral and maintains the price target from $16.5 to $16.5.</p>


Downgrades

TASK

Baird Downgrades TaskUs to Neutral, Maintains Price Target to $16.5

<p><strong>Blade Air Mobility Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) shares are trading higher on Monday after the company reported better-than-<a href="https://www.benzinga.com/pressreleases/25/05/g45343555/blade-air-mobility-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">expected first-quarter 2025 results</a>.</p>
<p>Revenue grew&nbsp;5.4%&nbsp;year-over-year (Y/Y) to&nbsp;$54.3 million, beating the consensus of&nbsp;$49.43 million.</p>
<p>Revenue growth was driven by growth in the Passenger segment. Excluding Canada, which exited in August 2024, revenue increased&nbsp;10.9%&nbsp;Y/Y.</p>
<p>Medical revenue declined 0.2% Y/Y&nbsp;to&nbsp;$35.9&nbsp;million. Short Distance revenue fell&nbsp;5.4%&nbsp;Y/Y to&nbsp;$9.3&nbsp;million, but excluding Canada, it grew&nbsp;28.1% Y/Y.</p>
<p>Jet and Other revenue surged&nbsp;59.9%&nbsp;to&nbsp;$9.1&nbsp;million&nbsp;on increased flight volumes and revenue per flight.</p>
<p>Flight Profit rose&nbsp;18.1% Y/Y&nbsp;to&nbsp;$12.0&nbsp;million, driven by growth in Passenger segments. Flight Margin improved to&nbsp;22.1%&nbsp;from&nbsp;19.7% in the quarter.</p>
<p>Adjusted EBITDA improved by&nbsp;$2.3&nbsp;million&nbsp;Y/Y to&nbsp;$(1.2)&nbsp;million, driven by improvements in the Passenger segment.</p>
<p>Quarterly net loss improved by&nbsp;$0.7&nbsp;million&nbsp;Y/Y to&nbsp;$(3.5)&nbsp;million, mainly due to a&nbsp;$2.3 million&nbsp;improvement in operating losses.</p>
<p>EPS&nbsp;loss of 4 cents exceeded the street <a href="https://www.benzinga.com/earnings">view of loss of 11 cents</a>.</p>
<p>Operating Cash Flow rose by&nbsp;$15.3&nbsp;million&nbsp;to&nbsp;$(0.2)&nbsp;million in the quarter. Capex was&nbsp;$3.2&nbsp;million due to aircraft maintenance and purchase of aircraft in the Medical Segment.</p>
<p>Free Cash Flow before aircraft acquisitions improved by&nbsp;$14.0&nbsp;million&nbsp;to&nbsp;$(2.7)&nbsp;million in the quarter.</p>
<p><strong>Rob Wiesenthal</strong>, Blade&#8217;s chief executive officer, said, &#8220;Our strong Passenger Segment results reflect several factors including our durable competitive positioning along with the important actions we&#8217;ve taken recently to improve profitability such as our exit from Canada and broad-based cost rationalization initiatives.&#8221;</p>
<p><strong>Will Heyburn</strong>, chief financial officer added, &#8220;Our Medical business is well positioned to prosper in the current environment given the strength of our logistics platform, strong underlying transplant volume growth, limited economic sensitivity and insulation from tariffs.&#8221;</p>
<p><strong>2025&nbsp;Outlook:</strong>&nbsp;Blade Air Mobility expects revenue of&nbsp;$245 million&nbsp;–&nbsp;$265 million&nbsp;versus consensus of&nbsp;$256.3 million&nbsp;and <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44301933/blade-air-mobility-soars-as-q4-revenue-beats-expectations-and-medical-segment-shines" rel="noreferrer noopener">double-digit Adjusted EBITDA.</a></p>
<p>Heyburn added, &#8220;We continue to expect improving results throughout the rest of the year in both business lines. In Medical, we are onboarding additional new customers and expect continued growth with existing customers. In Passenger, while the economic outlook may be uncertain, we still expect ongoing year-over-year benefits from cost and restructuring actions, as we will not anniversary our implementation of most items <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">until the fourth quarter of this year.</a>&#8220;</p>
<p><strong>Melissa Tomkiel</strong>, president, stated, &#8220;Following a period of unusually heavy scheduled aircraft maintenance and associated downtime during the first half of 2025, we expect a significant improvement in the second half of the year through 2026, resulting in reduced capital expenditures and improved Medical Segment Adjusted EBITDA margins.&#8221;</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>ARK Space Exploration &amp; Innovation ETF</strong>&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>).</p>
<p><strong>Price Action:</strong> BLDE shares are up 14.7% at $3.35 at the last check Monday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/25/02/43781179/joby-vs-archer-vs-blade-which-evtol-stock-is-ready-for-takeoff" target="_blank" rel="noreferrer noopener">Joby Vs. Archer Vs. Blade: Which eVTOL Stock Is Ready For Takeoff?</a></strong></li>
</ul>
<p><em>Image created using artificial intelligence via Midjourney.</em></p>


Earnings

Equities

Guidance

Small Cap

Movers

ARKX

BLDE

Blade Beats Q1 Forecasts As Jet Surge, Short Flights Drive Gains

<p>Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Eton Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $0.03.</p>
<p>The announcement from Eton Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.00 in the last quarter, leading to a 1.36% increase in the share price on the following day.</p>
<p>Here's a look at Eton Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.02</td>
<td>0.02</td>
<td>-0.12</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>16.0%</td>
<td>3.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747058590_0.png" alt="eps graph" /></p>
<h3>Performance of Eton Pharmaceuticals Shares</h3>
<p>Shares of Eton Pharmaceuticals were trading at $16.79 as of May 09. Over the last 52-week period, shares are up 360.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Eton Pharmaceuticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Eton Pharmaceuticals.</p>
<p>The consensus rating for Eton Pharmaceuticals is Buy, derived from 3 analyst ratings. An average one-year price target of $27.67 implies a potential 64.8% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Tilray Brands, with an average 1-year price target of $1.0, suggesting a potential 94.04% downside.</li>
<li>Analysts currently favor an Buy trajectory for Zevra Therapeutics, with an average 1-year price target of $22.0, suggesting a potential 31.03% upside.</li>
<li>Analysts currently favor an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $27.33, suggesting a potential 62.78% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eton Pharmaceuticals</td>
<td>Buy</td>
<td>59.26%</td>
<td>$6.48M</td>
<td>-2.96%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>-1.36%</td>
<td>$52.01M</td>
<td>-25.45%</td>
</tr>
<tr>
<td>Zevra Therapeutics</td>
<td>Buy</td>
<td>-6.79%</td>
<td>$10.68M</td>
<td>-65.31%</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>-17.39%</td>
<td>$10.77M</td>
<td>-14.91%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Eton Pharmaceuticals ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.</p>
<h3>Unveiling the Story Behind Eton Pharmaceuticals</h3>
<p>Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.</p>
<h3>Unraveling the Financial Story of Eton Pharmaceuticals</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Eton Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>59.26%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Eton Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-5.13%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Eton Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.96%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Eton Pharmaceuticals's ROA excels beyond industry benchmarks, reaching <strong>-1.07%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Eton Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>1.22</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/ETON/earnings"><strong>To track all earnings releases for Eton Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ETON

A Look Ahead: Eton Pharmaceuticals's Earnings Forecast

<p>Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Herbalife to report an <strong>earnings per share</strong> (EPS) of $0.41.</p>
<p>The market awaits Herbalife's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.14 in the last quarter, leading to a 42.7% increase in the share price on the following day.</p>
<p>Here's a look at Herbalife's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.41</td>
<td>0.22</td>
<td>0.35</td>
<td>0.41</td>
<td>0.34</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.59</td>
<td>0.36</td>
<td>0.57</td>
<td>0.54</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-8.0%</td>
<td>43.0%</td>
<td>11.0%</td>
<td>-9.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747058577_0.png" alt="eps graph" /></p>
<h3>Tracking Herbalife's Stock Performance</h3>
<p>Shares of Herbalife were trading at $6.73 as of May 09. Over the last 52-week period, shares are down 36.34%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HLF/earnings"><strong>To track all earnings releases for Herbalife visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Herbalife's Earnings Forecast

<p>INNO HOLDINGS INC. ("INNO" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>) is trade-focused building technology and electronic products trading company, dedicated to consistently seeking innovative ways to enhance services and technologies and delivers high-quality products to its customers.</p>
<p>INNO has announced strategic cooperation with New Life Technology Development Co Ltd ("New Life Tech"), a renowned electronic products supply chain management group in Hong Kong, on development of a cutting edge B2B marketplace platform that will facilitate manufacturers and distributors to sell direct to business buyers. This marketplace platform, empowered by cloud computing, big data, and high-frequency matchmaking technology, will provide sellers cutting edge marketplace technology to enhance and grow their business while offering buyers access to an exclusive collection of top brands at or below wholesale prices.</p>
<p>The strategic cooperation between INNO and New Life Tech signifies a strategic step forward in collaboration, particularly within the domain of electronic products supply chain services. This collaboration also opens avenues for exploration and innovation in various business sectors for INNO.</p>


INHD

INNO Announces Strategic Cooperation With New Life Tech On Development Of Cutting Edge B2B Marketplace Platform

<p>Guggenheim  analyst Jonathan Lee   reiterates DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) from Neutral to Neutral.</p>


Guggenheim Reiterates Neutral on DXC Technologyto Neutral

<p><strong>Intuitive Machines</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Intuitive Machines will report an <strong>earnings per share</strong> (EPS) of $-0.05. </p>
<p>Anticipation surrounds Intuitive Machines's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $2.00, leading to a 4.46% drop in the share price on the subsequent day.</p>
<p>Here's a look at Intuitive Machines's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.08</td>
<td>-0.01</td>
<td>-0.25</td>
<td>0.27</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-2.08</td>
<td>-0.83</td>
<td>0.29</td>
<td>-2.70</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>21.0%</td>
<td>-2.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747058555_0.png" alt="eps graph" /></p>
<h3>Performance of Intuitive Machines Shares</h3>
<p>Shares of Intuitive Machines were trading at $9.24 as of May 09. Over the last 52-week period, shares are up 70.72%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LUNR/earnings"><strong>To track all earnings releases for Intuitive Machines visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LUNR

An Overview of Intuitive Machines's Earnings

<p>AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>, AMPGW))), a leading designer, developer, and manufacturer of advanced signal processing components for satellite, public and private 5G, and other communications networks, including full 5G/6G system design and global distribution of integrated circuit assembly packages and lids, today proudly announces a significant milestone: the FCC Certification of its cutting-edge ORAN LPRU-Gen3-3537-AE-AI 5G radios. This achievement marks a pivotal moment for AmpliTech Group as it further solidifies its strategy to position the company as an ORAN 5G leader in the global 5G market.</p>
<p>The FCC Certification for ORAN LPRU-Gen3-3537-AE-AI radios underscores AmpliTech's commitment to innovation and excellence in telecommunications. These state-of-the-art radios are designed to meet the rigorous standards of performance, reliability, and regulatory compliance set by the Federal Communications Commission, ensuring seamless integration into next-generation 5G networks.</p>


AMPG

AmpliTech Group Achieves Major Milestone With FCC Certification Of Advanced ORAN LPRU-Gen3-3537-AE-AI 5G Radios

<p>DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate DoubleDown Interactive to report an <strong>earnings per share</strong> (EPS) of $0.55.</p>
<p>Investors in DoubleDown Interactive are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.13 in the last quarter, leading to a 7.31% drop in the share price on the following day.</p>
<p>Here's a look at DoubleDown Interactive's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.59</td>
<td>0.56</td>
<td>0.49</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.72</td>
<td>0.51</td>
<td>0.67</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747058546_0.png" alt="eps graph" /></p>
<h3>Tracking DoubleDown Interactive's Stock Performance</h3>
<p>Shares of DoubleDown Interactive were trading at $10.96 as of May 09. Over the last 52-week period, shares are up 0.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/DDI/earnings"><strong>To track all earnings releases for DoubleDown Interactive visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For DoubleDown Interactive

<p>Barclays  analyst Adrienne Yih   maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Overweight and lowers the price target from $254 to $223.</p>


Barclays Maintains Overweight on Dick's Sporting Goods, Lowers Price Target to $223

<p>Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Landstar System to report an <strong>earnings per share</strong> (EPS) of $0.96.</p>
<p>The market awaits Landstar System's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS missed by $0.03 in the last quarter, leading to a 3.46% drop in the share price on the following day.</p>
<p>Here's a look at Landstar System's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.34</td>
<td>1.45</td>
<td>1.45</td>
<td>1.28</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.31</td>
<td>1.41</td>
<td>1.48</td>
<td>1.32</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747058536_0.png" alt="eps graph" /></p>
<h3>Performance of Landstar System Shares</h3>
<p>Shares of Landstar System were trading at $135.56 as of May 09. Over the last 52-week period, shares are down 20.8%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Views on Landstar System</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Landstar System.</p>
<p>Analysts have given Landstar System a total of 8 ratings, with the consensus rating being Neutral. The average one-year price target is $142.38, indicating a potential 5.03% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Ryder System, Schneider National and Knight-Swift, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Ryder System, with an average 1-year price target of $163.0, suggesting a potential 20.24% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Schneider National, with an average 1-year price target of $24.5, suggesting a potential 81.93% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Knight-Swift, with an average 1-year price target of $50.82, suggesting a potential 62.51% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Ryder System, Schneider National and Knight-Swift, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Landstar System</td>
<td>Neutral</td>
<td>0.41%</td>
<td>$153.79M</td>
<td>4.65%</td>
</tr>
<tr>
<td>Ryder System</td>
<td>Neutral</td>
<td>0.71%</td>
<td>$616M</td>
<td>3.20%</td>
</tr>
<tr>
<td>Schneider National</td>
<td>Neutral</td>
<td>6.28%</td>
<td>$116.40M</td>
<td>0.87%</td>
</tr>
<tr>
<td>Knight-Swift</td>
<td>Neutral</td>
<td>0.10%</td>
<td>$246.20M</td>
<td>0.43%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Landstar System ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, Landstar System is positioned in the middle compared to its peers in the analysis.</p>
<h3>Unveiling the Story Behind Landstar System</h3>
<p>Landstar System is an agent based asset-light third-party logistics provider focused on domestic truck brokerage. Historically, around half of its truck transportation freight is hauled by leased owner-operators with the remainder hauled by third-party broker-carriers. To a smaller degree, it offers intermodal, global air and ocean forwarding, and warehousing services. Landstar also runs a small business that offers insurance programs to captive owner-operators. It has a long history of industry-leading execution and operating profitability.</p>
<h3>Financial Insights: Landstar System</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Landstar System's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>0.41%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Landstar System's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>3.82%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.65%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Landstar System's ROA excels beyond industry benchmarks, reaching <strong>2.59%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.17</strong>, Landstar System adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/LSTR/earnings"><strong>To track all earnings releases for Landstar System visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LSTR

What to Expect from Landstar System's Earnings

<p>Loar Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Loar Holdings to report an <strong>earnings per share</strong> (EPS) of $0.17.</p>
<p>The announcement from Loar Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 0.96% increase in the share price the following trading session.</p>
<p>Here's a look at Loar Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.11</td>
<td>0.13</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.11</td>
<td>0.15</td>
<td>0.09</td>
<td>11023.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>2.0%</td>
<td>1.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of Loar Holdings were trading at $95.88 as of May 09. Over the last 52-week period, shares are up 95.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Loar Holdings</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Loar Holdings.</p>
<p>Loar Holdings has received a total of 3 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $91.67, the consensus suggests a potential 4.39% downside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Huntington Ingalls Indus, StandardAero and Rocket Lab USA, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Huntington Ingalls Indus, with an average 1-year price target of $244.67, suggesting a potential 155.18% upside.</li>
<li>Analysts currently favor an Neutral trajectory for StandardAero, with an average 1-year price target of $30.0, suggesting a potential 68.71% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Rocket Lab USA, with an average 1-year price target of $24.67, suggesting a potential 74.27% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Huntington Ingalls Indus, StandardAero and Rocket Lab USA, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loar Holdings</td>
<td>Outperform</td>
<td>27.77%</td>
<td>$53.96M</td>
<td>0.40%</td>
</tr>
<tr>
<td>Huntington Ingalls Indus</td>
<td>Buy</td>
<td>-2.53%</td>
<td>$394M</td>
<td>3.16%</td>
</tr>
<tr>
<td>StandardAero</td>
<td>Neutral</td>
<td>21.75%</td>
<td>$201.91M</td>
<td>-0.79%</td>
</tr>
<tr>
<td>Rocket Lab USA</td>
<td>Neutral</td>
<td>32.13%</td>
<td>$35.25M</td>
<td>-14.90%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Loar Holdings ranks at the bottom for Revenue Growth among its peers. It is at the top for Gross Profit. For Return on Equity, it is at the bottom.</p>
<h3>About Loar Holdings</h3>
<p>Loar Holdings Inc in the design, manufacture, and sale of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Its manufactured products includes auto throttles, lap-belt airbags, two- and three-point seat belts, water purification systems, fire barriers, polyimide washers and bushings, latches, hold-open and tie rods, temperature and fluid sensors and switches, carbon and metallic brake discs, fluid and pneumatic-based ice protection, RAM air components, sealing solutions and motion and actuation devices, among others.</p>
<h3>Loar Holdings's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Loar Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>27.77%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Loar Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>3.34%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Loar Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.4%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Loar Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.25%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Loar Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.26</strong>.</p>
<p><a href="https://www.benzinga.com/quote/LOAR/earnings"><strong>To track all earnings releases for Loar Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LOAR

A Glimpse of Loar Holdings's Earnings Potential

UPLD

Upland Software shares are trading higher after the company reported better-than-expected Q1 financial results.

<p>CAE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that CAE will report an <strong>earnings per share</strong> (EPS) of $0.47.</p>
<p>Investors in CAE are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.01, leading to a 13.91% increase in the share price on the subsequent day.</p>
<p>Here's a look at CAE's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.20</td>
<td>0.13</td>
<td>0.16</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
<td>0.18</td>
<td>0.15</td>
<td>0.27</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>14.000000000000002%</td>
<td>11.0%</td>
<td>5.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747058517_0.png" alt="eps graph" /></p>
<h3>Market Performance of CAE's Stock</h3>
<p>Shares of CAE were trading at $25.94 as of May 09. Over the last 52-week period, shares are up 23.18%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CAE/earnings"><strong>To track all earnings releases for CAE visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For CAE

<p>Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Camtek to report an <strong>earnings per share</strong> (EPS) of $0.77.</p>
<p>The market awaits Camtek's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 1.62% increase in the share price the following trading session.</p>
<p>Here's a look at Camtek's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.75</td>
<td>0.69</td>
<td>0.64</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.77</td>
<td>0.75</td>
<td>0.66</td>
<td>0.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-6.0%</td>
<td>-9.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747058507_0.png" alt="eps graph" /></p>
<h3>Market Performance of Camtek's Stock</h3>
<p>Shares of Camtek were trading at $66.57 as of May 09. Over the last 52-week period, shares are down 25.74%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CAMT/earnings"><strong>To track all earnings releases for Camtek visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CAMT

An Overview of Camtek's Earnings

Events

Press Releases

5E Advanced Materials Management to Attend the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Management

ARRAY Technologies Names H. Keith Jennings as Chief Financial Officer

5E Advanced Materials Management to Attend Maxim Group's 2025 Mining Conference

Offerings

5E Advanced Materials Announces Funding Package and Proposed Restructure and Equitization of Convertible Notes

5E Advanced Materials Announces the Expected Appointment of Curtis Hébert to the Company's Board of Directors

5E Advanced Materials Reports Positive Progress, Unveils Strengthened Project Economics and Timeline to Final Investment Decision

5E Advanced Materials Management to Attend 37th Annual ROTH Conference

5E Advanced Materials to Present at the 15th Annual LD Micro Invitational Conference

5E Advanced Materials Boron Successfully Passes Specialty Glass Trial

5E Advanced Materials to Participate in "Critical Minerals Summit: Accelerating the Mining of U.S. Critical Minerals" Presented by Maxim Group on Tuesday, May 6th

ARRY

American Battery Technology Company - Common Stock

American Battery Tech

BHP Group Limited American Depositary Shares (Each representing two Ordinary Shares)

BHP Group

Compass Minerals Intl

Critical Metals

Contango Ore

Ferroglobe

Idaho Strategic Resources, Inc. Common Stock

Idaho Strategic Resources

Ivanhoe Electric

Ioneer

Snow Lake Resources

MP Materials

Materion

Nexa Res

Nova Minerals Limited - American Depositary Shares

Nova Minerals

Piedmont Lithium

TMC the metals company Inc. - Common Stock

TMC The Metals Co

United States Antimony Corporation Common Stock

United States Antimony

USA Rare Earth

U.S. Gold

US Goldmining

Solitario Resources

Maxim Group

DA Davidson

B. Riley Securities

Baird

<h3 class="wp-block-heading"><strong>2024년 5월 28일 주요 뉴스</strong></h3>
<p><strong>골드 로열티</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROY#NYSE">GROY</a>): 밴쿠버에 본사를 둔 이 회사는 오리온 마인 파이낸스(Orion Mine Finance)로부터 바레스 실버 프로젝트(<a href="https://www.benzinga.com/wiim/24/05/39035910/gold-royalty-shares-are-trading-lower-after-the-company-announced-that-it-entered-into-a-binding-agr" target="_blank" rel="noopener">Vares Silver Project</a>)의 구리 스트림을 5천만 달러에 구매하기로 합의했다. 지급액에는 현금 4,500만 달러와 500만 달러 상당의 골드 로열티 주식이 포함된다.</p>
<ul>
<li>이 스트림은 바레스(Vares)의 루피스(Rupice) 매장지에서 구리 생산량의 100%를 담당하며 LME 현물 구리 가격의 30%로 지속적인 지불을 제공한다.</li>
<li>첫 번째 정광 생산은 2024년 2월에 시작되었으며, 2024년 4분기에 상업 생산이 예상다.</li>
<li>아드리아틱 메탈스(Adriatic Metals)가 운영하는 바레스(Vares) 프로젝트는 광산 수명이 18년이며 2026년까지 연간 생산량을 100만 톤으로 늘릴 계획이다.</li>
</ul>
<p><strong>BHP</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>)와 리오 틴토(Rio Tinto)는 <strong>캐터필러</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)와 코마츠(Komatsu)의 협력하여 서부 호주의 필바라(Pilbara)에서 배터리 전기 트럭을 테스트할 예정이다.</p>
<ul>
<li>2024년에 CAT 793 트럭 2대, 2026년에 코마츠 930 트럭 2대로 시작되는 이 시험은 이들 트럭의 성능과 생산성을 평가하는 것이 목적이다.</li>
<li>이번 협력은 2050년까지 운영상 순배출량 제로를 달성하려는 두 회사의 목표를 지원한다.</li>
<li>결과는 BHP와 리오 틴토 간에 공유되어 향후 배터리 전기 운반 트럭의 대규모 배치를 알릴 것이다.</li>
</ul>
<p><strong>메탈스 에퀴지션</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTAL#NYSE">MTAL</a>)은 폴리메탈 리소스(Polymetals Resources Limited, POL)의 지분 4.31%에 주당 35 호주센트로 250만 호주달러를 투자하고 있으며, 두 번째 투자는 여러 계약과 엔데버(Endeavour) 광산 재개를 위한 자금 조달을 조건으로 250만 호주달러를 투자한다. 이 호주 광산 및 탐사업체는 지분이 7%를 초과하면 이사회 자리를 얻게 된다.</p>
<ul>
<li>이번 투자에는 4.5년 동안 아연광석 및 연간 150ML의 물 공급을 담당하게 된다.</li>
<li>POL은 상당한 인프라를 갖추고 역사적으로 은, 아연, 납을 생산해 온 엔데버 광산을 다시 시작하는 것을 목표로 하고 있다.</li>
<li>이러한 전략적 움직임은 MAC의 CSA 구리 광산 운영 가치를 높이는 것을 목표로 한다.</li>
</ul>
<p><strong>5E 어드밴스드 머티리얼스</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEAM#NASDAQ">FEAM</a>)은 600만 달러의 선순위 전환사채를 발행하고 있다.</p>
<ul>
<li>블루스케이프 에너지 파트너스(Bluescape Energy Partners)와 어센드 글로벌 인베스트먼트 펀드 SPC(Ascend Global Investment Fund SPC)는 각각 2028년 8월 만기 주당 1.53달러에 보통주로 전환 가능한 300만 달러 상당의 채권을 매입할 예정이며 이자는 10% 현물 지급된다.</li>
<li>이 자금은 소규모 시설, FEL-2 엔지니어링 및 상업 계약을 위한 고객 자격을 지원하는 한편 이 회사는 정부 자금을 모색한다.</li>
</ul>
<p><em>기업소식:</em> <a href="https://www.benzinga.com/government/24/05/39029408/us-military-invests-15-million-in-canadian-mineral-projects-to-secure-critical-resources"><em>미국 군, 캐나다 광물 프로젝트로 1,500만 달러 투자</em></a></p>
<p><strong><em>Benzinga Mining은 광업 기업과 일반 투자자 간의 연결을 돕는 플랫폼입니다. <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a>을 통해 Benzinga 커뮤니티와 연결하세요!</em></strong></p>

Comments

5E Advanced Materials

뉴스

에 대한 최신 뉴스 5E Advanced Materials (NASDAQ:FEAM) 주식

화요일, 5월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌